Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Biotechnology

Healthcare
$247.77 +0.02%

+$0.05 today

Market cap
$15.90B
Beta
0.33
P/E (TTM)
476.3
EPS (TTM)
$0.48
52W Low $105.00High $243.32

Volume 0.72M

Average 0.92M

JAZZ Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Jazz Pharmaceuticals plcNASDAQ: JAZZ

Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026

Cost of revenue remains negative

Q3 FY2026 cost of revenue was $0, compared with $257.76M a year earlier. Trailing-twelve-month cost of revenue was $447.45M. Over 3 fiscal years it compounded at -2.4% a year.

Context

  • Cost of revenue amounted to 11.8% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $111.86M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$503.3M+12.9% YoY
LTMSep 2026
$447.45M-26.3% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+12.9%——
3-year CAGR-2.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
503.3M USD
Year-over-year change
+12.9%
4-year CAGR
+3.4%

Cost of Revenue vs competitors

How JAZZ compares with its peers on the latest reported figures

  • JAZZ's LTM Sep 2026 cost of revenue of $447.45M is the 2nd highest of the 9 companies compared; the peer median is $195.42M.
  • Its year-over-year change of -26.3% is the 7th highest of 8, against a peer median of +41.0%.
  • Cost of revenue amounts to 9.5% of revenue for JAZZ, versus a peer median of 12.3%.
JAZZ Competitors Peer median
Cost of Revenue for JAZZ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$584.36M +63.0%+84.1%43.0%
JAZZJazz Pharmaceuticals plcLTM Sep 2026$447.45M -26.3%-2.4%9.5%
INCYIncyte CorporationLTM Jun 2026$429.56M +31.6%+21.6%7.4%
GMABGenmab A/SLTM Jun 2026$288M ——7.0%
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 2026$235.91M +41.0%+33.4%24.6%
TGTXTG Therapeutics, Inc.LTM Sep 2026$154.93M +98.5%+624.3%17.3%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$81.2M +85.4%+31.0%2.2%
MGNXMacroGenics, Inc.LTM Mar 2026$47.23M -18.4%+80.2%30.1%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 2026$4.12M -82.2%-50.0%1.4%
Peer median (excluding JAZZ) $195.42M+41.0%+33.4%12.3%

Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.09B3.66B3.83B4.07B4.27B
Cost of Revenue440.76M540.52M435.58M445.71M503.3M
Gross Profit2.65B3.12B3.4B3.62B3.76B
Gross Margin85.8%85.2%88.6%89.0%88.2%
Research & Development505.75M590.45M849.66M884M782.74M
Selling, General & Admin1.45B1.42B1.34B1.39B1.81B
Operating Expenses2.48B3.18B2.82B2.91B3.54B
Depreciation & Amortization552.48M629.47M638.7M660.07M696.3M
EBITDA1.03B1.47B1.45B1.52B262.76M
EBITDA Margin33.2%40.1%37.8%37.4%6.2%
Operating Income170.28M(65.53M)578.58M716.63M224.42M
Operating Margin5.5%-1.8%15.1%17.6%5.3%
Interest Income00000
Interest Expense278.77M288.24M289.44M238.1M195.05M
Other Income / Expenses(283.83M)(317.18M)(283.66M)(247.94M)(853.01M)
Income Before Tax(113.55M)(382.71M)294.92M468.69M(628.59M)
Pre-Tax Margin-3.7%-10.5%7.7%11.5%-14.7%
Income Tax Expense216.12M(158.65M)(119.91M)(91.43M)(272.44M)
Net Income(328.95M)(224.06M)414.83M560.12M(356.15M)
Net Margin-10.6%-6.1%10.8%13.8%-8.3%
EPS (Basic)(5.51)(3.58)6.559.06(5.84)
EPS (Diluted)(5.51)(3.58)6.108.65(5.84)
Weighted Avg Shares59.69M62.54M63.29M61.84M60.98M
Weighted Avg Shares (Diluted)59.69M62.54M72.07M66.01M60.98M

Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Intrinsic Alpha fair value

Locked

Current Price

$247.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.